Chemoimmunotherapy (CIT) has been the cornerstone of the first-line (1L) treatment for CLL and SLL for almost a decade. However, on the basis of several recent randomized phase III trials, CIT is being replaced by treatment with regimens based on targeted therapy such as the Bruton tyrosine kinase inhibitors, B-cell leukemia/lymphoma-2 inhibitors, and anti-CD20 antibodies. While these agents demonstrated significantly better efficacy than CIT in terms of longer progression-free survival, the problems associated with their use include a specific spectrum of side effects, the need for long-term therapy, and a significant economic burden.
Oncology nursing professionals play key roles in ensuring patients achieve optimal outcomes. Join us for breakfast, in which expert clinicians evaluate the emerging standard of care for 1L treatment of CLL and SLL, provide guidance for identifying and monitoring for treatment-emergent adverse events, and share best practices for engaging patients in risk-benefit assessment.